COVID-19 Resources

Interim Guidance for COVID-19 and Persons with HIV – U.S. Department of Health and Human Services, April 21, 2020

COVID-19 and People Living with HIV, Frequently Asked Questions, May 5, 2020, (FAQs by AIDS United, HIVMA, Latino Commission on AIDS, NASTAD, NMAC, Positive Women’s Network, Prevention Access Campaign, TransLatin@ Coalition, US PLHIV Caucus, and The Well Project)

COVID-19:  Special Considerations for People Living with HIV – IDSA and HIVMA, April 17, 2020

EACS & BHIVA Statement on risk of COVID-19 for people living with HIV (PLWH) – April 1, 2020

What does COVID-19 mean for people living with HIV: online information – HIV i-Base, March 27, 2020

Children’s HIV Association (CHIVA) statement on COVID-19 and HIV – March 24, 2020

Resources you need for COVID-19 and HIV – AVAC, March 23, 2020

Gender and COVID-19 Resources – Gender and COVID-19 Working Group

People Who Use Drugs and Drug Service Providers

EMCDDA update on the implications of COVID-19 for people who use drugs (PWUD) and drug service providers – The European Monitoring Centre for Drugs and Drug Addiction

Syringe Services Programs (SSPs), Drug User Health, and COVID-19 – National Alliance of State and Territorial AIDS Directors (NASTAD)

Harm Reduction

Coronavirus and drug harm reduction – Transform Drug Policy Foundation

Resources for drug use and COVID-19 risk reduction – Vital Strategies

Correctional and Detention Facilities

COVID-19 Guidance for Correctional and Detention Facilities – CDC

Tracking Public Investment in Global COVID-19 R&D – UAEM, SNMA, AMSA

COVID-19 Research Registry – American Society for Microbiology

Ongoing Studies for the Treatment and Prevention of the COVID-19 Virus – AVAC

COVID-19 Treatment and Vaccine Tracker – Milken Institute

STAT News COVID-19 Drugs and Vaccines Tracker

COVID-19 Clinical Trials Explorer – Jesse Burk Rafel, MD, MRes and Marina Marin, MS

Covid-19 TrialsTracker – The DataLab in collaboration with the Centre for Evidence-Based Medicine (CEBM) at the University of Oxford

Scientist.com Trial Tracker

Review and methodological analysis of trials currently testing treatment and prevention options for the novel coronavirus disease (COVID-19) globally – Paraskevi C. Fragkou et al, medRxiv, May 06, 2020

Ongoing Clinical Trials for the Management of the COVID-19 Pandemic – Mark P. Lythgoe and Paul Middleton, Trends in Pharmacological Sciences, April 11, 2020

SARS-CoV-2 Diagnostic Pipeline – FIND

SARS-CoV-2 Molecular Assay Evaluation: Results

Emergency Use Authorized Serology Test Performance – US Food and Drug Administration

IDSA COVID-19 Antibody Testing Primer

Developing a National Strategy for Serology (Antibody Testing) in the United States – The Johns Hopkins Center for Health Security

Ten reasons why immunity passports are a bad idea – Natalie Kofler & Françoise Baylis, Nature, May 21, 2020

What Antibody Studies Can Tell You — and More Importantly, What They Can’t – Caroline Chen, ProPublica, April 28

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease – Angkana T. Huang et al, medRxiv, April 17, 2020

Treatment Action Group Statement on the High Price of Cepheid’s Xpert Test for COVID-19 – March 27, 2020 

Illustrated diagnostics glossary (pp.56-69) – Treatment Action Group

COVID-19 therapeutics tracker – Jeff Craven, Regulatory Focus

Coronavirus Disease 2019 (COVID-19) Treatment Guidelines – National Institutes of Health, May 12, 2020

Treatment of SARS-CoV-2: How far have we reached? – Waquar Ahsan et al, Drug Discoveries & Therapeutics, April 30, 2020

Adjunct immunotherapies for the management of severely ill COVID-19 patients – Srinivasa Reddy Bonam et al, Cell Reports Medicine, April 30, 2020

Systematic Review of the Efficacy and Safety of Antiretroviral Drugs Against SARS, MERS or COVID-19: Initial Assessment – Nathan Ford et al, JIAS, March 26, 2020

Treatment Action Group Statement on HIV Treatments and SARS-CoV-2/COVID-19 – March 25, 2020

Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics – Andre C. Kalil, JAMA, March 24, 2020

DRAFT landscape of COVID-19 candidate vaccines – World Health Organization

COVID-19 Vaccine Tracker – Jeff Craven, Regulatory Focus

VAXMAP: An open source-based map of COVID-19 candidate vaccines and manufacturing capacity

Unveiling ‘Warp Speed,’ the White House’s America-first push for a coronavirus vaccine – Jon Cohen, Science, May 12, 2020

Rapid COVID-19 vaccine development – Barney S. Graham, Science, May 8, 2020

The race for coronavirus vaccines: a graphical guide – Ewen Callaway, Nature, April 28, 2020

Antibody testing will enhance the power and accuracy of COVID-19-prevention trials – Marc Lipsitch, Rebecca Kahn & Michael J. Mina, Nature Medicine, April 27, 2020

The hunt for a coronavirus vaccine – a perilous and uncertain path – Hannah Devlin, The Guardian, April 24, 2020

The COVID-19 vaccine development landscape – Tung Thanh Le et al,  Nature Reviews Drug Discovery, April 9, 2020

Developing Covid-19 Vaccines at Pandemic Speed – Nicole Lurie et al, NEJM, March 30, 2020

Coronavirus vaccines: five key questions as trials begin – Ewen Callaway, Nature, March 18, 2020

Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees – Shibo Jiang, Nature, March 16, 2020

Coronavirus COVID-19 Global Cases – Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)

The COVID Tracking Project

COVID-19 Projections Using Machine Learning – Youyang Gu